Lv1
30 积分 2025-02-19 加入
Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences
12天前
已完结
Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives
1个月前
已完结
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
1个月前
已完结
Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
1个月前
已完结
Obinutuzumab in systemic lupus erythematosus: a real-world experience
3个月前
已完结
Observation of rituximab as initial treatment in patients with minimal change disease- a retrospective study
4个月前
已完结
Membranous nephropathy
5个月前
已完结
Novel treatment options in rituximab-resistant membranous nephropathy patients
7个月前
已完结
Treatment of Idiopathic Membranous Nephropathy for Moderate or Severe Proteinuria: A Systematic Review and Network Meta-Analysis
7个月前
已完结
Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives
7个月前
已完结
皖公网安备34019202002308
